veNTIlATIoN - Green Cross Publishing

product news
52
Micardis (telmisartan) approved by the
EC to reduce the risk of cardiovascular
morbidity in high risk patients
Micardis is now indicated by the European Commission for
the reduction of CV morbidity in patients with manifest
atherothrombotic CV disease or type 2 diabetes with
documented target organ damage.
• Micardis (telmisartan) is the ONLy treatment in its
class with this indication, demonstrating proven
cardiovascular (CV) protection in patients at high
CV risk
• This new indication is based on a review of clinical
trials, including results from the ONTARGET trial
• Patients at-risk of heart attack and stroke can now
benefit from this new indication.
Ingelheim, Germany, 27 November 2009: Boehringer
Ingelheim announced today that the European
Commission has approved Micardis (telmisartan) for the
reduction of cardiovascular morbidity in patients with:
I. manifest atherothrombotic cardiovascular disease
(history of coronary heart disease, stroke, or
peripheral arterial disease) or,
II. type 2 diabetes mellitus with documented target
organ damage.
Micardis is the first treatment in its class to be approved
for this indication.
Professor Giuseppe Mancia, Professor of Medicine and
Chairman of the Department of Clinical Medicine of the
University of Milan, Bicocca, Italy said, “This new indication
of telmisartan is a significant development for physicians
and their at-risk patients. Prevention of CV events is vital
as these are the primary causes of pathological death
in Europe, due to lack of proper control of treatable risk
factors and disease. The approval of telmisartan offers
patients a well-tolerated treatment option which also
provides CV protection.”
The European Commission approval is based upon a
review of clinical trial results, including the ONTARGET
trial involving 25,620 patients and confirmed Micardis
as the only treatment option in its class with proven
cardiovascular protective effects in patients with high CV
risk. The results also demonstrated that Micardis is better
tolerated than the previous gold standard ramipril and is
associated with higher treatment adherence.
Approximately 10,000 people in Ireland die each year
from cardiovascular disease making it the leading cause of
death in Ireland, accounting for 36% of all deaths.
Micardis is one of the most studied antihypertensives
in clinical trials and is widely used with over five million
patient years since its approval. Its safety profile is similar
to that of placebo.
Cubitan, new evidence demonstrates
faster healing of pressure ulcers in
nourished patients
Nutricia Advanced Medical Nutrition has
announced seminal research on Cubitan,
the only oral nutritional supplement
(ONS) specifically indicated for the dietary
management of wounds, which could
change the way healthcare professionals
treat patients with pressure ulcers. Results
from a randomised controlled trial (CUBE
trial) reveal that Cubitan promotes faster
healing of pressure ulcers in nourished
patients compared to standard wound
care treatment. Cubitan also results in
significantly fewer dressings and less
nursing time spent on wound care which suggests potential
cost savings with its usage.
Professor Jos Schols, the lead investigator from Maastricht
University, The Netherlands, comments that, “It is an
important trial for us as previous studies on ONS in pressure
ulcer healing have focused on malnourished patients, which
meant it was difficult to establish whether the benefits seen
were a result of correcting malnutrition. As the CUBE trial
focused on non-malnourished patients we know that the
benefits seen are a result of Cubitan affecting the wound
itself and not due to correcting deficiencies. Not only are
these results interesting from a clinical point of view, but
the data on wound dressings indicates there may be an
economic benefit of using Cubitan – something we are keen
to investigate further”.
This new research was announced just weeks after further
data from Italy demonstrated more effective wound healing
with Cubitan over a standard enteral nutritional formula.
Cubitan is the only nutritional intervention specially
indicated for the dietary management of wounds and it
should be used in both the prevention and treatment of
wounds. At €2.07 Cubitan is the same price as all other high
protein oral nutritional supplements but it contains the
highest amount of wound specific nutrients; zinc, vitamin C,
vitamin E and arginine.
Clonfolic 0.4mg 28 pack
Clonmel Healthcare wish to inform you that from 1 st February
2010 Clonfolic 0.4mg 28 pack will no longer be available as a
GMS reimbursable Product. Clonfolic 0.4mg 28 pack will still be
available as an OTC product only.
Please rest assured that the 98 pack size of Clonfolic 0.4mg
remains GMS reimbursable.
If you have any queries please contact 01-620 4000.
www.yourmedicines.ie